By Cole Bunn, Research Analyst, LSN
Life science angel investors have long been a fundamental piece of a fundraising campaign, typically providing strategic guidance and capital to entrepreneurs who are right out of the gate. Relaxed crowdfunding provisions and big pharma’s increased involvement in early-stage companies, among other developments, has created new opportunities for angels to find, fund and exit biotech companies. This crucial investor class speaks to the types of deals they like to do, what it’s like to work with an angel investor and how they see the biotech and investment landscapes evolving.
To hear directly from the investors, watch the RESI video recap here: